In a major milestone for the psychedelic intellectual property community, Porta Sophia has been recognized as an official prior art resource by the United States Patent and Trademark Office (USPTO).
Read Psychedelic Alpha Article
Once criminalized, psychedelic therapies are now a booming industry. But how do scientists adopt and patent medical practices that have been around for millennia? We speak with a panel of guests on decolonizing psychedelics and how patenting drugs impacts the industry, culture and treatment.
Listen to WPR Cast
Global sales of antidepressant drugs are expected to exceed $20 billion by 2030. Now, some investors are betting that psychedelic therapies can grab a share of that enormous market.
Watch cNBC Special
Cash rich start-ups are filing scores of patent claims on hallucinogens like magic mushrooms. Researchers and patient advocates worry high prices will make the therapies unaffordable.
Read NYT Article
The Patent Trial and Appeal Board decided that petitions against Compass Pathways' psilocybin patents would not move forward to trial.
Read VICE Article
Porta Sophia is building an online database and searchable library of historical, scientific and cultural information pertaining to psychedelics that they say will support the work of both innovators and patent examiners.
Read Lucid News Article
Corporations are going to use IP law to profit from psychedelics. But creative strategies from other industries could help people push back against exclusionary ownership and keep drugs accessible.
Read VICE Article
In the fall of 2020, longtime patent attorney David Casimir started a non-profit organization called Porta Sophia along with co-founder Bill Linton to fight what they consider to be “bad” patents on psychedelics...
Read Microdose Interview
Compass Pathways has been aggressively using patent claims to corner the market on psychedelic-assisted treatments.
Read American Prospect Article